Skip to content

Clinical effectiveness of newer pulpotomy agents

Clinical effectiveness of Concentrated Growth Factor and injectable bioceramic material compared to MTA as pulpotomy agent in Permanent Mature Molar with Symptomatic Irreversible Pulpitis- a randomized controlled clinical trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/04/042044
Enrollment
81
Registered
2022-04-21
Start date
Unknown
Completion date
Unknown
Last updated
2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K040- Pulpitis

Interventions

Intervention1: Injectable bioceramic material , Concentrated Growth Factor prepared from autologous blood of individual: Injectable bioceramic material as one intervention group, Concentrated Growth

Sponsors

S B Divya
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1)Patients with symptomatic Irreversible Pulpitis of age 18 to 40 years permanent mature molar teeth with symptomatic irreversible pulpitis 2)Both Maxillary and Mandibular molar teeth. 3) A clinical diagnosis consistent with irreversible pulpitis will be established in all cases based on a history of severe spontaneous lingering pain that could be reproduced by cold testing. 4)Teeth which are tender to percussion can be included but those with periapical lesions, resorption of root must be excluded.

Exclusion criteria

Exclusion criteria: 1)Patients 2)Patients of age > 40 years of age 3)Medically compromised patients 4)Pregnant and lactating women. 5)Patients undergoing fixed orthodontic therapy 6)Patients with facial deformity including cleft lip/palate. 7)Teeth with apical periodontitis. 8)Teeth with fracture or crack lines. 9)Teeth with abrasion on the same tooth.

Design outcomes

Primary

MeasureTime frame
Post operative pain , tenderness and swelling (yes or no) Pain will be assessed using Visual Analog Scale (VAS) Timepoint: Post operative pain will be assessed after 24 hours and 48 hours, tenderness and swelling (yes or no)will be checked after 48 hours and 3 months Pain will be assessed using Visual Analog Scale (VAS)

Secondary

MeasureTime frame
Presence of periapical lesions at 3, 6 & 12 months recall. Dentin bridge formation at 12 months interval through CBCT radiographic analysis. Timepoint: 3,6,12 months

Countries

India

Contacts

Public ContactDr M S Nivedhitha

Saveetha Dental College and Hospitals

nivedhithamallisureshbabu@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026